These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6115915)

  • 1. Lowering of dopamine metabolites in rat brain by harmaline.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    J Pharm Pharmacol; 1981 Apr; 33(4):255-6. PubMed ID: 6115915
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW; Hemrick-Luecke SK
    Life Sci; 1985 Sep; 37(12):1089-96. PubMed ID: 3875779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of harmaline on the ability of pargyline to alter catecholamine metabolism in rats.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    Biochem Pharmacol; 1981 Jun; 30(11):1295-8. PubMed ID: 7271828
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhanced selectivity of pargyline as an inhibitor of type B monoamine oxidase in harmaline-treated rats.
    Fuller RW; Hemrick SK
    Life Sci; 1978 Mar; 22(12):1083-6. PubMed ID: 642716
    [No Abstract]   [Full Text] [Related]  

  • 5. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice.
    Fuller RW; Wong CJ; Hemrick-Luecke SK
    Life Sci; 1986 Feb; 38(5):409-12. PubMed ID: 3945167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline.
    Green AL; El Hait MA
    Biochem Pharmacol; 1980 Oct; 29(20):2781-9. PubMed ID: 6893669
    [No Abstract]   [Full Text] [Related]  

  • 7. Depletion of epinephrine in rat hypothalamus by Ro 4-1284: influence of pargyline and harmaline.
    Fuller RW; Hemrick-Luecke SK
    Brain Res Bull; 1980; 5(5):589-91. PubMed ID: 6903452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of monoamine oxidase in catecholamine-stimulated prostaglandin biosynthesis of rat brain homogenates.
    Komlós M; Seregi A; Schaefer A
    J Pharm Pharmacol; 1980 Aug; 32(8):592-3. PubMed ID: 6106705
    [No Abstract]   [Full Text] [Related]  

  • 9. Antagonism between harmaline and longacting monoamine oxidase inhibitors concerning the effect on 5-hydroxytryptamine and norepinephrine metabolism in the brain.
    PLETSCHER A; BESENDORF H
    Experientia; 1959 Jan; 15(1):25-6. PubMed ID: 13619675
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition patterns of monoamine oxidase in sub-fractions of rat brain mitochondria in presence of some selective inhibitors.
    Mitra C; Guha SR
    Biochem Pharmacol; 1979 Apr; 28(7):1135-7. PubMed ID: 444271
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of drugs on the temperature-lowering effect of harmaline.
    Bruinvels J; Sourkes TL
    Eur J Pharmacol; 1968 Aug; 4(1):31-9. PubMed ID: 5692910
    [No Abstract]   [Full Text] [Related]  

  • 12. Could harmaline generate tremor by affecting 5HT release? [proceedings].
    Headley PM; Lodge D
    Br J Pharmacol; 1979 May; 66(1):116P-117P. PubMed ID: 454912
    [No Abstract]   [Full Text] [Related]  

  • 13. Modification by harmaline of the effects of N-cyclopropyl-p-chloro-amphetamine on 5-hydroxyindole concentration in rat brain.
    Fuller RW; Hemrick SK; Perry KW
    J Pharm Pharmacol; 1979 Jan; 31(1):53-4. PubMed ID: 32371
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain.
    Nguyen TB; Angers M
    Biochem Pharmacol; 1987 May; 36(10):1731-5. PubMed ID: 3109430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harmaline-induced amnesia: Possible role of the amygdala dopaminergic system.
    Nasehi M; Meskarian M; Khakpai F; Zarrindast MR
    Neuroscience; 2016 Jan; 312():1-9. PubMed ID: 26556066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [3H]Harmaline as a specific ligand of MAO A--I. Properties of the active site of MAO A from rat and bovine brains.
    Nelson DL; Herbet A; Pétillot Y; Pichat L; Glowinski J; Hamon M
    J Neurochem; 1979 Jun; 32(6):1817-27. PubMed ID: 448370
    [No Abstract]   [Full Text] [Related]  

  • 17. N-[2-(o-iodophenoxy)ethyl]cyclopropylamine hydrochloride (LY121768), a potent and selective irreversible inhibitor of type A monoamine oxidase.
    Fuller RW; Hemrick-Luecke SK; Molloy BB
    Biochem Pharmacol; 1983 Apr; 32(7):1243-9. PubMed ID: 6847714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.
    Glick SD; Kuehne ME; Raucci J; Wilson TE; Larson D; Keller RW; Carlson JN
    Brain Res; 1994 Sep; 657(1-2):14-22. PubMed ID: 7820611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells.
    Lee CS; Han ES; Jang YY; Han JH; Ha HW; Kim DE
    J Neurochem; 2000 Aug; 75(2):521-31. PubMed ID: 10899927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of MAO inhibitors on impeding synaptosomal withdrawal and on dopamine metabolism in rat and human brain].
    Tóthfalusi L; Tekes K; Gaál J; Magyar K
    Acta Pharm Hung; 1989; 59 Suppl 1():75-9. PubMed ID: 2641638
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.